Welcome to our dedicated page for Numinus Wellness news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on Numinus Wellness stock.
Numinus Wellness Inc. (NUMIF) is a leader in developing evidence-based psychedelic-assisted therapies for mental health conditions. This dedicated news hub provides investors and stakeholders with centralized access to official updates and strategic developments.
Track critical announcements including clinical trial milestones, regulatory progress, partnership agreements, and financial performance reports. Our curated collection ensures efficient monitoring of Numinus' advancements in depression, anxiety, and trauma treatments through integrated clinic networks and research initiatives.
Key updates cover three strategic pillars: clinical research breakthroughs validating therapeutic protocols, clinic network expansions enhancing patient access, and practitioner training programs ensuring treatment quality. Receive timely alerts on patent filings, research collaborations, and operational optimizations.
Bookmark this page for streamlined tracking of Numinus' progress in transforming mental healthcare through FDA-compliant research and reimbursable treatment models. Visit regularly to stay informed about this innovative leader in psychedelic-assisted therapy development.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced its participation in the Wonderland conference in Miami from November 3-5, 2022. Dr. Reid Robison, Chief Clinical Officer, will present on the neurobiological differences between classic psychedelics and ketamine on November 5 at 9:50 a.m. ET. Numinus focuses on innovative mental health treatments, facilitating access to safe psychedelic-assisted therapies and aims to integrate these therapies into mainstream clinical practice, addressing conditions like depression and anxiety.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announced the launch of its Ketamine for Chronic and Serious Medical Illness Program, aimed at providing ketamine-assisted therapy to patients suffering from terminal conditions and chronic pain. Initially available in clinics across Utah, British Columbia, and Quebec, the program seeks to integrate therapy with existing care to improve overall patient wellbeing. The company is also consolidating its operations following the acquisition of Novamind, aiming for better service delivery and reduced costs.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) announced that its Founder and CEO, Payton Nyquvest, will participate in a Water Tower Research Fireside Chat on October 13, 2022, at 2:30 p.m. ET. The discussion will center around Numinus' strategic acquisition of Novamind and the growth opportunities it presents. Investors can register here.
On October 5, 2022, Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced the development of a psilocybin-containing tea bag for clinical research and potential therapeutic use. Designed for accessibility, especially for patients needing palliative care, this product allows precise dosing of 25mg per use, made from validated Psilocybe cubensis strains. Numinus aims to include this product in Health Canada's psilocybin supplier list to enhance access to psychedelic-assisted therapies.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF), a leader in mental health care, will participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022, in San Francisco. Founder and CEO Payton Nyquvest will feature in the Digital-Pharma and a New Way of Thinking for NeuroPsych panel on October 7 at 9:00 a.m. PT. Numinus will also partake in a virtual fireside chat during the Cantor Symposium on Mental Health Clinics on October 11, 2022, at 11:00 a.m. ET. The company focuses on innovative, evidence-based psychedelic-assisted therapies aimed at mental health improvement.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) has launched ketamine-assisted therapy at its Neurology Centre of Toronto to assist patients with neurologic conditions. This initiative leverages NCT's established infrastructure and aims to address mental health challenges associated with neurologic disorders. The clinic will follow a modified protocol for ketamine therapy, focusing on conditions like epilepsy and concussion. Additionally, NCT is set to expand psychedelic-assisted therapy access through Health Canada's Special Access Program, which includes promising treatments like psilocybin for depression.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) has reported significant growth following its acquisition of Novamind, which was completed on June 10, 2022. In August, the company recorded over 6,200 client appointments, a 25% increase compared to July, with 4,900 appointments at its eight US wellness clinics. Numinus is launching new financing options in Canada to enhance accessibility for clients. The company plans to rebrand its physical clinics by the end of 2022. Financial results for its fourth quarter will be disclosed on November 29, 2022.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, at the Lotte New York Palace Hotel. Numinus will present on September 13 at 9:00 a.m. ET. Interested attendees can register here. Numinus is dedicated to advancing mental health care through innovative and evidence-based psychedelic-assisted therapies.
Numinus Wellness Inc. reported a 32% year-over-year revenue growth to $0.74 million for Q3 2022, driven by a 59.5% increase in clinic network revenues. With a 24.4% gross margin reflecting $180,845 in gross profit, the company ended the quarter with $41.8 million in cash. The acquisition of Novamind, finalized on June 10, 2022, positions Numinus as a leader in psychedelic-assisted therapies, expected to enhance revenue and operational growth towards profitability within two years.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF), a leader in innovative mental health care, will announce its financial results for Q3 2022 on July 14, 2022, after market close. A conference call and webcast will follow at 5:30 p.m. ET to discuss performance and initiatives. Interested participants can register for the live session and access the archived version later. Numinus aims to transform mental health treatment through psychedelic-assisted therapies, focusing on healing rather than merely managing symptoms.
FAQ
What is the current stock price of Numinus Wellness (NUMIF)?
What is the market cap of Numinus Wellness (NUMIF)?
